Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Express Scripts
Boehringer Ingelheim
Harvard Business School
Federal Trade Commission
UBS
US Department of Justice
Daiichi Sankyo
Farmers Insurance
Deloitte

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,425,934

« Back to Dashboard

Which drugs does patent 8,425,934 protect, and when does it expire?


Patent 8,425,934 protects BRILINTA and is included in one NDA. There have been two Paragraph IV challenges on Brilinta.

This patent has thirty-five patent family members in thirty countries.

Summary for Patent: 8,425,934

Title:Pharmaceutical compositions
Abstract: The present invention relates to pharmaceutical compositions and, more particularly, to a pharmaceutical composition containing the compound {1S-[1.alpha.,2.alpha.,3.beta.(1S*,2R*),5.beta.]}-3-(7-{[2-(3,4-difluorop- henyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-- 3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.
Inventor(s): Banks; Simon (Loughborough, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:11/841,030
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca Pharms
BRILINTA
ticagrelor
TABLET;ORAL022433-002Sep 3, 2015RXYesNo► Subscribe► SubscribeY
Astrazeneca Pharms
BRILINTA
ticagrelor
TABLET;ORAL022433-001Jul 20, 2011RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,425,934

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Philippines12013501627► Subscribe
New Zealand596700► Subscribe
New Zealand574514► Subscribe
Norway20090425► Subscribe
Malaysia147966► Subscribe
Mexico340403► Subscribe
Mexico2009001853► Subscribe
Lithuania2056832► Subscribe
South Korea20090055561► Subscribe
Japan2014040448► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Cantor Fitzgerald
Accenture
Fish and Richardson
Teva
Fuji
US Army
Citi
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot